Find recruiting clinical trials for Parkinson's in the UK — from early-stage disease-modifying therapies to advanced treatment options. See where trials fit into your care pathway.
Free to use · Live data from ClinicalTrials.gov · Updated daily
See where clinical trials fit into your care journey
When symptoms first require medication
Standard: Levodopa (co-beneldopa/co-careldopa), dopamine agonists (pramipexole, ropinirole), or MAO-B inhibitors (rasagiline, selegiline)
When levodopa wears off or causes unpredictable responses
Standard: COMT inhibitors (entacapone, opicapone), MAO-B inhibitors, or dopamine agonists added to levodopa
For significant motor complications despite optimised oral therapy
Standard: Apomorphine infusion, levodopa-carbidopa intestinal gel (LCIG), or deep brain stimulation (DBS)
Trials aiming to slow or stop disease progression — the Holy Grail of Parkinson's research
Standard: No approved disease-modifying treatment yet — trials are critical
A progressive neurological condition caused by the loss of dopamine-producing cells in the brain. Affects about 153,000 people in the UK. Symptoms include tremor, stiffness, slowness of movement, and balance problems.
Current treatments manage symptoms but don't slow progression. Clinical trials are testing disease-modifying therapies, gene therapies, focused ultrasound, and novel drug delivery systems that could transform outcomes.
Parkinson's also causes sleep problems, depression, anxiety, constipation, and cognitive changes. Many trials now target these non-motor symptoms, which can be as debilitating as the movement problems.
Loading trials from ClinicalTrials.gov...